Giovanni B. Frisoni

📖 Wiki Page

researcher750 wordssynced 2026-04-02

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Giovanni B. Frisoni</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Geneva</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Switzerland</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-4565-4925" target="_blank">0000-0002-4565-4925</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Neuroimaging, [Biomarkers](/mechanisms/biomarkers-ad), Clinical trials</td>
</tr>
</table>

Giovanni B. Frisoni

Overview

...

Giovanni B. Frisoni

Overview

Mermaid diagram (expand to render)

Giovanni B. Frisoni is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Geneva. Their research focuses on Neuroimaging, Biomarkers, Clinical trials, with particular emphasis on Alzheimer's Disease. With an h-index of 180, Frisoni is among the most cited researchers in the neuroscience field["@orcid2026"].

Frisoni's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Neuroimaging, Biomarkers, Clinical trials, publishing in high-impact journals including leading neuroscience journals.

Based at University of Geneva, Frisoni collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.

Research Focus

Disease Areas

[Alzheimer's Disease](/diseases/alzheimers-disease)

Mechanisms of Interest

Neuroimaging
[Biomarkers](/biomarkers)
Clinical trials

Programmatic Emphasis

Frisoni's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant[@jack2018].

The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.

Methods and Data Strategy

Within the Neuroimaging, Biomarkers, Clinical trials domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.

The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.

Translational Relevance

For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.

This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.

Key Publications

[PubMed author search for Giovanni B. Frisoni](https://pubmed.ncbi.nlm.nih.gov/?term=Giovanni+B.+Frisoni%5BAuthor%5D)[@orcid2026]

[Google Scholar author search for Giovanni B. Frisoni](https://scholar.google.com/scholar?q=author%3A%22Giovanni+B.+Frisoni%22)[@orcid2026]

[Semantic Scholar profile search for Giovanni B. Frisoni](https://www.semanticscholar.org/search?q=Giovanni+B.+Frisoni)[@orcid2026]

Recent Research

Recent PubMed-indexed publications (2022-present):

[Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41765956/). European journal of nuclear medicine and molecular imaging. 2026.

[Dopaminergic deficits along the spectrum of Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/39890920/). Molecular psychiatry. 2025.

[Resilience in Alzheimer's disease: Impact of operationalization and methodological choices.](https://pubmed.ncbi.nlm.nih.gov/40289834/). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.

[The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.](https://pubmed.ncbi.nlm.nih.gov/40243238/). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.

[RADAR-AD: assessment of multiple remote monitoring technologies for early detection of Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/39865315/). Alzheimer's research & therapy. 2025.

Collaborators and Research Network

Collaborator network pending enrichment.

Institutional Context

Primary institutional links: [University of Geneva](/university-of-geneva). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.

Open Questions and Future Directions

How can Neuroimaging, Biomarkers, Clinical trials signals be standardized across cohorts and sites without losing disease-stage sensitivity?
Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?

External Links

ORCID: [https://orcid.org/0000-0002-4565-4925](https://orcid.org/0000-0002-4565-4925)
Google Scholar: [Search for Giovanni B. Frisoni](https://scholar.google.com/scholar?q=author%3A%22Giovanni+B.+Frisoni%22)
PubMed: [Author search for Giovanni B. Frisoni](https://pubmed.ncbi.nlm.nih.gov/?term=Giovanni+B.+Frisoni%5BAuthor%5D)

References

Unknown, ORCID profile for Giovanni B. Frisoni (2026)

[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)

[Jack et al, NIA AA research framework toward a biological definition of Alzheimer disease 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29653606/)

📖 View canonical wiki page →

Giovanni B. Frisoni

Giovanni B. Frisoni

Overview

Giovanni B. Frisoni

Overview

Research Focus

Disease Areas

Mechanisms of Interest

Programmatic Emphasis

Methods and Data Strategy

Translational Relevance

Key Publications

Recent Research

Collaborators and Research Network

Institutional Context

Open Questions and Future Directions

External Links

See Also

References